Alto Neuroscience Appoints New CMO, Adds Director

TL;DR

Alto Neuro just hired a new CMO and added a director to the board. Big moves for their pipeline.

AI Summary

Alto Neuroscience, Inc. announced on March 8, 2024, the appointment of Dr. David Kupfer as Chief Medical Officer and the election of Ms. Jennifer McNeley to its Board of Directors. Dr. Kupfer, formerly of Genentech, brings extensive experience in neuroscience drug development. Ms. McNeley, a seasoned executive, will serve on the Audit Committee.

Why It Matters

The appointment of a new Chief Medical Officer and a new board member with relevant experience can signal a strategic shift or strengthening of leadership for the company's drug development pipeline.

Risk Assessment

Risk Level: medium — Changes in key executive and board positions can indicate internal shifts that may impact future strategy and performance.

Key Players & Entities

• Alto Neuroscience, Inc. (company) — Registrant
• Dr. David Kupfer (person) — Appointed Chief Medical Officer
• Ms. Jennifer McNeley (person) — Elected to Board of Directors
• Genentech (company) — Former employer of Dr. Kupfer

FAQ

From the Filing

0001193125-24-064372.txt : 20240311 0001193125-24-064372.hdr.sgml : 20240311 20240311082003 ACCESSION NUMBER: 0001193125-24-064372 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240308 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20240311 DATE AS OF CHANGE: 20240311 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alto Neuroscience, Inc. CENTRAL INDEX KEY: 0001999480 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 834210124 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41944 FILM NUMBER: 24736632 BUSINESS ADDRESS: STREET 1: 369 SOUTH SAN ANTONIO RD. CITY: LOS ALTOS STATE: CA ZIP: 94022 BUSINESS PHONE: 773-255-5012 MAIL ADDRESS: STREET 1: 369 SOUTH SAN ANTONIO RD. CITY: LOS ALTOS STATE: CA ZIP: 94022 8-K 1 d764642d8k.htm 8-K 8-K false 0001999480 0001999480 2024-03-08 2024-03-08     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2024     ALTO NEUROSCIENCE, INC. (Exact Name of Registrant as Specified in its Charter)       Delaware   001-41944   83-4210124 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)   369 South San Antonio Road , Los Altos , CA   94022 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code: (650) 200-0412 N/A (Former name or former address, if changed since last report.)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.0001 par value per share   ANRO   New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On March 8, 2024, the Board of Directors (the “Board”) of Alto Neuroscience, Inc. (the “Company”), following the recommendation of the Nominating and Corporate Governance Committee of the Board (the “NCGC”), appointed Maha Radhakrishnan, M.D., to serve as a member of the Board and as a member of the NCGC. Dr. Radhakrishnan was appointed as a Class I director for a term expiring at the Company’s 2025 Annual Meeting of Stockholde